Indaptus Therapeutics (NASDAQ:INDP) Stock Price Down 9.6% – Here’s What Happened

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s share price traded down 9.6% during mid-day trading on Monday . The stock traded as low as $2.25 and last traded at $2.27. 36,569 shares traded hands during trading, a decline of 84% from the average session volume of 225,293 shares. The stock had previously closed at $2.51.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on INDP shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Indaptus Therapeutics to a “sell” rating in a research report on Saturday, October 25th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Indaptus Therapeutics presently has an average rating of “Sell”.

Indaptus Therapeutics Price Performance

The company has a 50 day simple moving average of $3.15 and a 200-day simple moving average of $7.24. The firm has a market cap of $2.29 million, a PE ratio of -0.05 and a beta of 1.00.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($2.98) EPS for the quarter, topping the consensus estimate of ($4.17) by $1.19. On average, sell-side analysts predict that Indaptus Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.

Institutional Trading of Indaptus Therapeutics

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent quarter. Institutional investors own 7.06% of the company’s stock.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.